Pharmaceutical cost dynamics for the treatment of rifampicin-resistant tuberculosis in children and adolescents in South Africa, India, and the Philippines

被引:0
|
作者
Wilkinson, Thomas [1 ]
Garcia-Prats, Anthony J. [2 ,3 ]
Sachs, Tina [3 ]
Paradkar, Mandar [4 ,5 ]
Suryavanshi, Nishi [4 ,5 ]
Kinikar, Aarti [6 ]
Frias, Melchor V. [7 ]
Sinanovic, Edina [1 ]
Hesseling, Anneke C. [3 ]
Seddon, James. A. [3 ,8 ]
Palmer, Megan [3 ]
机构
[1] Univ Cape Town, Sch Publ Hlth & Family Med, Hlth Econ Unit, Cape Town, South Africa
[2] Univ Wisconsin Madison, Sch Med & Publ Hlth, Dept Pediat, Madison, WI USA
[3] Stellenbosch Univ, Fac Med & Hlth Sci, Desmond Tutu TB Ctr, Dept Paediat & Child Hlth, Stellenbosch, South Africa
[4] Johns Hopkins Univ Clin Res Site, Byramjee Jeejeebhoy Govt Med Coll, Pune, Maharashtra, India
[5] Johns Hopkins India, Ctr Infect Dis India, Pune, India
[6] Byramjee Jeejeebhoy Govt Med Coll Sassoon Gen Hos, Dept Paediat, Pune, Maharashtra, India
[7] De La Salle Med & Hlth Sci Inst, Res Div, Dasmarinas City, Cavite, Philippines
[8] Imperial Coll London, Dept Infect Dis, London, England
来源
PLOS ONE | 2024年 / 19卷 / 07期
关键词
REGIMENS; DISEASE;
D O I
10.1371/journal.pone.0305930
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Rifampicin-resistant (RR) tuberculosis (TB) in children is a major global health concern but is often neglected in economics research. Accurate cost estimations across the spectrum of paediatric RR-TB treatment regimens are critical inputs for prioritisation and budgeting decisions, and an existing knowledge gap at local and international levels. This normative cost analysis was nested in a Phase I/II pharmacokinetics, safety, tolerability, and acceptability trial of TB medications in children in South Africa, the Philippines and India. It assessed the pharmaceutical costs of 36 childhood RR-TB regimens using combinations from 16 different medicines in 34 oral formulations (adult and child-friendly) in 11 weight bands in children <15 years of age. The analysis used local and Global Drug Facility pricing, and local and international guideline recommendations, including adaptions of BPaL and BPaLM regimens in adults. Costs varied significantly between regimen length, age/weight banding, severity of disease, presence of fluroquinolone resistance, and different country guideline recommendations. WHO recommended regimen costs ranged 12-fold: from US$232 per course (short regimen in non-severe disease) to US$2,761 (long regimen in severe, fluroquinolone-resistant disease). Regimen treating fluoroquinolone-resistant infection cost US$1,090 more than comparable WHO-recommended regimen. Providing child-friendly medicine formulations in <5-year-olds across all WHO-recommended regimens is expected to cost an additional $380 (range $212-$563) per child but is expected to have wider benefits including palatability, acceptability, adherence, tolerability, and dose accuracy. There were substantial differences in regimen affordability between countries when adjusted for purchasing power and domestic spending on health. Appropriate, effective, and affordable treatment options are an important component of the fight against childhood RR-TB. A comprehensive understanding of the cost and affordability dynamics of treatment options will enable national TB programs and global collaborations to make the best use of limited healthcare resources for the care of children with RR-TB.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda
    Ngabonziza, J-C S.
    Habimana, Y. M.
    Decroo, T.
    Migambi, P.
    Dushime, A.
    Mazarati, J. B.
    Rigouts, L.
    Affolabi, D.
    Ivan, E.
    Meehan, C. J.
    Van Deun, A.
    Fissette, K.
    Habiyambere, I
    Nyaruhirira, A. U.
    Turate, I
    Semahore, J. M.
    Ndjeka, N.
    Muvunyi, C. M.
    Condo, J. U.
    Gasana, M.
    Hasker, E.
    Torrea, G.
    de Jong, B. C.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2020, 24 (03) : 329 - +
  • [42] Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes
    Decroo, Tom
    Maug, Aung Kya Jai
    Hossain, Mohamed Anwar
    Uwizeye, Cecile
    Gumusboga, Mourad
    Demeulenaere, Tine
    Ortuno-Gutierrez, Nimer
    de Jong, Bouke C.
    Van Deun, Armand
    PLOS ONE, 2020, 15 (08):
  • [43] Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis
    Hughes, Jennifer A.
    Solans, Belen P.
    Draper, Heather R.
    Schaaf, H. Simon
    Winckler, Jana L.
    Van der Laan, Louvina
    Radtke, Kendra K.
    Fourie, Barend
    Wiesner, Lubbe
    Hesseling, Anneke C.
    Savic, Radojka M.
    Garcia-Prats, Anthony J.
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (10) : 1772 - 1780
  • [44] "Take the treatment and be brave": Care experiences of pregnant women with rifampicin-resistant tuberculosis
    Loveday, Marian
    Hlangu, Sindisiwe
    Furin, Jennifer
    PLOS ONE, 2020, 15 (12):
  • [45] Clofazimine and QT prolongation in the treatment of rifampicin-resistant tuberculosis: Findings of aDSM in Taiwan
    Lin, Chou-Jui
    Chen, Jin-Hua
    Chien, Shun-Tien
    Huang, Yi-Wen
    Lin, Chih-Bin
    Lee, Jen-Jyh
    Lee, Chih-Hsin
    Yu, Ming-Chih
    Chiang, Chen-Yuan
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2024, 57 (05) : 791 - 800
  • [46] Comment on: The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis
    Akkerman, O. W.
    Alffenaar, J. W. C.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (03) : 834 - 834
  • [47] Rifampicin-resistant tuberculosis treatment: way forward without hampering future options?
    Decroo, T.
    Mesic, A.
    de Jong, B. C.
    Rigouts, L.
    Gils, T.
    Mallick, J.
    Lynen, L.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2021, 26 : 255 - 255
  • [48] Impact of rpoB gene mutations and Rifampicin-resistance levels on treatment outcomes in Rifampicin-resistant tuberculosis
    Vadakunnel, Maria Jose
    Nehru, Vijayalakshmi Jawaharlal
    Brammacharry, Usharani
    Ramachandra, Venkateswari
    Palavesam, Suganthi
    Muthukumar, Anbazhagi
    Mani, Balasundaram Revathi
    Sriramkumar, S. R.
    Pradhabane, Gunavathy
    Dusthackeer, V. N. Azger
    Subramani, Sangeetha
    Muthaiah, Muthuraj
    Soundappan, Govindarajan
    BMC INFECTIOUS DISEASES, 2025, 25 (01)
  • [49] Management of rifampicin-resistant TB: programme indicators and care cascade analysis in South Africa
    De Vos, E.
    Scott, L.
    De Lima, Y. Voss
    Warren, R. M.
    Stevens, W.
    Hayes, C.
    da Silva, P.
    Van Rie, A.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2021, 25 (02) : 134 - +
  • [50] Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis
    Garcia-Prats, Anthony J.
    Garcia-Cremades, Maria
    Cox, Vivian
    Kredo, Tamara
    Dunbar, Rory
    Schaaf, H. Simon
    Seddon, James A.
    Furin, Jennifer
    Achar, Jay
    Radke, Kendra
    Sachs, Tina
    Abubakirov, Amanzhan
    Ahmed, Saman
    Akkerman, Onno W.
    Al Ani, Nadia Abdulkareem
    Amanullah, Farhana
    Ahmad, Nafees
    Anderson, Laura F.
    Asfaw, Meseret
    Bango, Funeka
    Bauer, Torsten
    Becerra, Mercedes
    Boeree, Martin
    Brinkmann, Folke
    Brown, Rosemary
    Brust, James
    Campbell, Jonathon R.
    Carvalho, Anna Cristina
    Carvalho, Isabel
    Cegielski, J. Peter
    Centis, Rosella
    Chan, Edward D.
    Chauhan, Sandeep
    Chiang, Silvia S.
    Chan, Pei-Chun
    D'Ambrosio, Lia
    Dalcolmo, Margareth
    Daneilyan, Narine
    de Vries, Gerard
    Draper, Heather R.
    Fairlie, Lee
    Francis, Joshua R.
    Franke, Molly
    Gegia, Medea
    Restrepo, Camilo Gomez
    Guenther, Annette
    Gureva, Tatyana
    Haecker, Brit
    Harausz, Elizabeth
    Hewison, Catherine
    LANCET CHILD & ADOLESCENT HEALTH, 2025, 9 (02): : 100 - 111